Background
prostate cancer death, mCRPC, castrate-resistant prostate cancer
METASTATIC PROSTATE CANCER, CASTRATE-RESISTANT PROSTATE CANCER
Black men are at higher risk for prostate cancer death. Previous studies showed a benefit of different therapies, including immune-based therapy, for Black men with metastatic prostate cancer. We sought to explore the efficacy of the PD-L1 inhibitor avelumab in Black men with metastatic castrate-resistant prostate cancer (mCRPC) progressing after abiraterone or enzalutamide.